Last reviewed · How we verify
Control - Crossover to CCH
This is a crossover study comparing a control arm to collagenase clostridium histolyticum (CCH) treatment for Peyronie's disease.
This is a crossover study comparing a control arm to collagenase clostridium histolyticum (CCH) treatment for Peyronie's disease. Used for Peyronie's disease with penile curvature deformity.
At a glance
| Generic name | Control - Crossover to CCH |
|---|---|
| Also known as | Collagenase Clostridium Histolyticum |
| Sponsor | Charitable Union for the Research and Education of Peyronie's Disease |
| Drug class | Collagenase enzyme |
| Target | Collagen (types I and III) |
| Modality | Small molecule |
| Therapeutic area | Urology / Sexual Medicine |
| Phase | FDA-approved |
Mechanism of action
This appears to be a clinical trial design rather than a distinct drug entity. CCH is a collagenase enzyme that degrades collagen in penile plaques characteristic of Peyronie's disease, reducing curvature and improving erectile function. The 'Control - Crossover to CCH' designation suggests patients in a control arm were subsequently crossed over to receive active CCH treatment.
Approved indications
- Peyronie's disease with penile curvature deformity
Common side effects
- Penile pain or hematoma at injection site
- Penile swelling or bruising
- Corporal fibrosis or erectile dysfunction
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |